REGENXBIO, Inc. Forecast, price target & analysts
REGENXBIO, Inc. Target price 2025 - Analyst rating & recommendation
REGENXBIO, Inc. Classifications & Recommendation:
REGENXBIO, Inc. Price Target
| Target Price | $32.13 |
| Price | $8.39 |
| Potential |
282.96%
register free of charge
|
| Number of Estimates | 14 |
|
14 Analysts have issued a price target REGENXBIO, Inc. 2026 .
The average REGENXBIO, Inc. target price is $32.13.
This is
282.96%
register free of charge
$54.60
550.77%
register free of charge
$13.13
56.50%
register free of charge
|
|
| A rating was issued by 18 analysts: 16 Analysts recommend REGENXBIO, Inc. to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the REGENXBIO, Inc. stock has an average upside potential 2026 of
282.96%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 83.33 | 355.88 |
| 7.66% | 327.07% | |
| EBITDA Margin | -256.97% | 6.93% |
| 7.55% | 102.70% | |
| Net Margin | -272.53% | -0.72% |
| 6.66% | 99.74% |
14 Analysts have issued a sales forecast REGENXBIO, Inc. 2025 . The average REGENXBIO, Inc. sales estimate is
This results in the following potential growth metrics:
9 Analysts have issued an REGENXBIO, Inc. EBITDA forecast 2025. The average REGENXBIO, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
14 REGENXBIO, Inc. Analysts have issued a net profit forecast 2025. The average REGENXBIO, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -4.59 | -0.05 |
| 23.75% | 98.91% | |
| P/E | negative | |
| EV/Sales | 0.44 |
14 Analysts have issued a REGENXBIO, Inc. forecast for earnings per share. The average REGENXBIO, Inc. EPS is
This results in the following potential growth metrics and future valuations:
REGENXBIO, Inc....
Current REGENXBIO, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Chardan Capital |
Locked
➜
Locked
|
Locked | Jun 09 2025 |
| Goldman Sachs |
Locked
➜
Locked
|
Locked | Apr 17 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 21 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 20 2025 |
| Chardan Capital |
Locked
➜
Locked
|
Locked | Mar 20 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 17 2025 |
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Mar 14 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Chardan Capital:
Locked
➜
Locked
|
Jun 09 2025 |
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
Apr 17 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 21 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 20 2025 |
|
Locked
Chardan Capital:
Locked
➜
Locked
|
Mar 20 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 17 2025 |
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Mar 14 2025 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
